Imagen de Portada

Prevalence and prognosis of patients with MASLD ‐related cirrhosis after an ICU hospitalization in France: A single‐centre prospective study

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Philippe Sultanik, Guillaume Lherault, Charlotte Bouzbib, Vlad Ratziu, Raluca Pais, Sarah Mouri, Dominique Thabut, Marika Rudler
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Editorial: Quantity is important! Authors' reply
por: Marika Rudler, et al.
Publicado: (2024)

Other causes of neurocognitive impairment than covert hepatic encephalopathy ( CHE ) are very frequent, either alone or associated with CHE , in cirrhotic patients with cognitive complaints
por: Philippe Sultanik, et al.
Publicado: (2024)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
por: Darren Jun Hao Tan, et al.
Publicado: (2024)

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
por: Maral Amangurbanova, et al.
Publicado: (2024)

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
por: Lana Bridi, et al.
Publicado: (2024)

Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
por: Xiaojuan Liu, et al.
Publicado: (2025)

Repeatability of vibration‐controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study
por: Harris Siddiqi, et al.
Publicado: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed
por: Haibo Jing, et al.
Publicado: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply
por: Andrea Martini, et al.
Publicado: (2024)

Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial
por: Elliot B. Tapper, et al.
Publicado: (2024)

Prospective evaluation of patients with non‐cirrhotic portal hypertension: A single centre study
por: Maria Mironova, et al.
Publicado: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
por: Mingsi Zhang, et al.
Publicado: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients
por: Ming‐Lun Yeh, et al.
Publicado: (2024)

Editorial: Terlipressin and MDRO colonisation in cirrhosis—Is there a causal link?
por: Luciano Revelli, et al.
Publicado: (2024)

Review article: Evaluation and care of the critically ill patient with cirrhosis
por: Iva Kosuta, et al.
Publicado: (2024)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
por: Mark C. C. Cheah, et al.
Publicado: (2025)

Editorial: Cardiometabolic criteria matters inMASLD
por: Margaret L. P. Teng, et al.
Publicado: (2024)

Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
por: Maryam Zafer, et al.
Publicado: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
por: Elliot B. Tapper, et al.
Publicado: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
por: Linda Henry, et al.
Publicado: (2024)

Review article: Recent advances in ascites and acute kidney injury management in cirrhosis
por: Danielle Adebayo, et al.
Publicado: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
por: Jiru Li, et al.
Publicado: (2025)

Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
por: Hannah Mohr, et al.
Publicado: (2025)

Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis
por: Dominik Bettinger, et al.
Publicado: (2024)

Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance
por: Senlin Ye, et al.
Publicado: (2024)

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes
por: Suzanne Sharpton, et al.
Publicado: (2026)

Editorial: Accelerometers to Quantify Physical Activity in MASLD—Impact on Clinical Outcomes
por: Vincent L. Chen
Publicado: (2025)

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study
por: R. Sinha, et al.
Publicado: (2025)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
por: Hassan Javed, et al.
Publicado: (2025)

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
por: Wah‐Kheong Chan, et al.
Publicado: (2024)

Terlipressin therapy is associated with increased risk of colonisation with multidrug‐resistant bacteria in patients with decompensated cirrhosis
por: Marcus M. Mücke, et al.
Publicado: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
por: Jian Wang, et al.
Publicado: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find
por: Leya Nedumannil, et al.
Publicado: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
por: Lukas Burghart, et al.
Publicado: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
por: Nobuharu Tamaki, et al.
Publicado: (2025)

Editorial: Refining the Natural History of MASLD by Imaging‐Based Markers: The GOLDMINE Study
por: Federico Perna, et al.
Publicado: (2026)

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
por: Takefumi Kimura
Publicado: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
por: Mohamed El‐Kassas, et al.
Publicado: (2025)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
por: Mary Yue Wang, et al.
Publicado: (2025)

Editorial: Enriching our understanding of MASLD through representation of under‐reported populations
por: Niharika Samala, et al.
Publicado: (2024)